- Home
- ITRG vs TLSA Comparison
ITRG vs TLSA Comparison
Compare ITRG & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRG | TLSA |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | Canada | United Kingdom |
| Employees | N/A | 9 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 874.5M | 155.2M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ITRG | TLSA |
|---|---|---|
| Price | $3.15 | $1.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.13 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 93.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $733.38 | N/A |
| Revenue Next Year | $46.00 | N/A |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $0.73 |
| 52 Week High | $4.87 | $2.60 |
Technical Indicators
Market Signals| Indicator | ITRG | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 33.13 | 35.66 |
| Support Level | $2.62 | N/A |
| Resistance Level | $3.30 | $1.56 |
| Average True Range (ATR) | 0.23 | 0.10 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 1.55 | 9.46 |
Price Performance
Historical ComparisonAbout ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.